GlaxoSmithKline (GSK.L) has invited private equity firms to consider making offers for a range of its older drugs sold in Western markets, according to three people with direct knowledge of the matter.
The move is part of a reshaping of the drugmaker’s business, which also involves a major asset swap deal struck last month with Novartis (NOVN.VX).
{iframe}http://www.reuters.com/article/2014/05/29/us-gsk-drugs-idUSKBN0E91MK20140529{/iframe}